Loading...
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a...
Na minha lista:
| Udgivet i: | Diabetes Metab Syndr Obes |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475096/ https://ncbi.nlm.nih.gov/pubmed/31118715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S174568 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|